Emerging Health Care Issues: Follow-On Biologic Drug Competition: A Federal Trade Commission Report
News release: “The Federal Trade Commission today released a report entitled, Emerging Health Care Issues: Follow-on Biologic Drug Competition, which examines whether the price of biologic drugs products manufactured using living tissues and microorganisms could be reduced by competition from so-called follow-on biologics (FOBs). FOBs are like generic drugs, but with significant differences. …